Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

A panelist discusses how detailed clinical assessments of hematologic parameters, symptom burden, thrombotic risk, and molecular markers inform necessary treatment modifications when initial ...